Prevalence and phylogenetic analysis of HTLV-1 in blood donors in Golestan Province, in the Northeast of Iran

Habibabadi, Hossein Mehrabi; Parsania, Masoud; Pourfathollah, Ali Akbar; Bahrami, Asma; Sharifi, Zohreh

doi:10.1016/j.jviromet.2021.114073

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Emadi et al reported an HTLV-1 prevalence in 4 per 100,000 among 263,465 blood donors aged between 18 and 25 years old, while 66 per 100,000 donors of 46 to 65 years old [51]. Conversely, some studies with considerable sample sizes (from 407 to 35,067 individuals) reported no significant relationship between participants' age and the infection rate [23,36,47,54]. An age-and sex-matched case-control study to assess the HTLV-1 risk factors among "firsttime" Iranian blood donors was performed during the period 2011-2012 [65].…”

Section: Resultsmentioning

confidence: 97%

Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran

Hedayati-Moghaddam

Esfehani

Hajj

et al. 2022

Viruses

View full text Add to dashboard Cite

Background: The epidemiology and prevalence of the Human T-cell leukemia virus type-1 (HTLV-1) infection represent a recommended priority by global health agencies. An in-depth revision to update the status of this infection in countries including those of the Eastern Mediterranean Regional Office (EMRO) of the World Health Organization is hence required. Methods: Ninety-seven studies evaluating the HTLV-1 infection in low- and high-risk populations in EMRO countries were retrieved from the international electronic databases and were used to assess the epidemiological status of the infection in these countries. Results: Most epidemiologic reports were published from Iran, with more than 50% of Iranian prisoners and around 4% of healthy individuals reported to have the infection. In Egypt, a considerable prevalence of the virus spans around 1.11% of blood donors. Foci of HTLV-1 infection are also present in some countries and require a careful epidemiological evaluation. In the other EMRO countries, a lower prevalence that does not exceed 1% was reported. Conclusion: The epidemiology and prevalence of HTLV-1 in the EMRO countries require a tight revision and update. Published studies reveal a scarce distribution of the virus in the African countries of EMRO, while a lower prevalence is denoted in the Asian countries of EMRO, except in Iran, where the prevalence is high.

show abstract